demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
breast cancer - triple negative
es-BC - TNBC - NA - all populationes-BC - TNBC - NA - PDL1 positivemBC - TNBC - L1 - all populationmBC - TNBC - L1 - PDL1 positive
atezolizumab based treatment
atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus nab-paclitaxel IMpassion-130 ... IMpassion-130 ...
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide IMpassion-031 ... IMpassion-031 ...
atezolizumab plus paclitaxel